Home Biosimilar Antibodies Others Antibody-Drug Conjugate Datopotamab deruxtecan
For research use only. Not for use in humans.

Datopotamab deruxtecan

Synonyms: DS-1062；DS-1062A

Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC.

Datopotamab deruxtecan

CAS No. 2238831-60-0

Click to purchase products related to Datopotamab deruxtecan

Quality Control

Batch: Purity: 99% Protein concentration: 14.37mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC.
References

Product Details

CAS No. 2238831-60-0
DAR 4.2
ADC antiody Datopotamab
ADC linker A tetrapeptide-based linker
ADC cytotoxin Dxd
Formulation 100 mM Pro-Ac，20 mM Arg，pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07069595 RECRUITING Drug: Datopotamab deruxtecan Breast Cancer; Residual Disease; Triple Negative Breast Cancer (TNBC); Stage II/III UNC Lineberger Comprehensive Cancer Center 2026-02-26 PHASE2
NCT01042379 RECRUITING Drug: Standard Therapy|Drug: AMG 386 with or without Trastuz Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer QuantumLeap Healthcare Collaborative 2010-03-01 PHASE2
NCT07720284 RECRUITING Drug: Dato-DXd|Drug: Rilvegostomig|Drug: Durvalumab|Drug: Ni High-risk Muscle Invasive Urothelial Carcinoma AstraZeneca 2026-07-16 PHASE3
NCT05215340 ACTIVE_NOT_RECRUITING Drug: Datopotamab Deruxtecan|Drug: Pembrolizumab Metastatic Non Small Cell Lung Cancer Daiichi Sankyo 2022-03-04 PHASE3
NCT06357533 RECRUITING Drug: Datopotamab Deruxtecan|Drug: Rilvegostomig|Drug: Pembr Non-Small Cell Lung Cancer AstraZeneca 2024-04-11 PHASE3
NCT07738341 NOT_YET_RECRUITING Drug: GB268|Drug: Nab-Paclitaxel|Drug: Datopotamab Deruxteca Breast Cancer (Locally Advanced or Metastatic) Eddingpharm (Zhuhai) Co., Ltd. 2026-08-01 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.